Overview: Anti-LGI1 TestIntroduction: The Anti-LGI1 Test checks for antibodies causing autoimmune encephalitis, leading to seizures, memory loss, or confusion, helping diagnose this brain inflammation disorder. Affecting 1 in 100,000 people annually, this condition poses diagnostic challenges due to its mimicry of epilepsy or psychiatric disorders, particularly in middle-aged adults. Following 2023 National Institute of Neurological Disorders and Stroke (NINDS) guidelines, it uses immunofluorescence for high specificity, supporting immunology screening. This test is critical for diagnosis, treatment planning, and improving outcomes in neurology, especially in acute care.
Other Names: Anti-LGI1 Antibody Test, LGI1 Encephalitis Assay.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic reliability.
Historical Milestone: Antibody testing for encephalitis began in the 2000s with research by Angela Vincent, who identified anti-LGI1 in limbic encephalitis cases. Immunofluorescence advancements in the 2010s by companies like Euroimmun improved detection, surpassing earlier radioimmunoassay methods that lacked sensitivity for LGI1 autoantibodies.
Purpose: Detects anti-LGI1 antibodies to diagnose autoimmune encephalitis, guides immunotherapy with steroids or IVIG, and evaluates patients with seizures, memory loss, or confusion, aiming to reduce brain inflammation and prevent long-term deficits.
Test Parameters: Anti-LGI1 antibody levels
Pretest Condition: No special preparation required to reflect natural antibody levels. Collect serum or cerebrospinal fluid (CSF). Report history of seizures or cognitive dysfunction.
Specimen: Serum (SST, 2-5 mL), CSF (sterile container, 1-2 mL); 2 mL serum in SST or 1 mL CSF in sterile container. Transport in a biohazard container to prevent degradation.
Sample Stability at Room Temperature: 6 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document seizures or cognitive dysfunction. Include current medications, recent infections, or family history of autoimmune diseases, noting any recent psychiatric symptoms.
Consent: Written consent required, detailing the test's purpose, encephalitis risks (e.g., coma, memory loss), and potential risks of sample collection, with emphasis on prompt treatment and neurological monitoring.
Procedural Considerations: Uses immunofluorescence to detect anti-LGI1 antibodies, requiring laboratories with fluorescent microscopes and trained immunologists. Results are available in 3-5 days, supporting acute care. Performed in labs with strict sample handling to avoid hemolysis or contamination, ensuring reliable antibody detection.
Factors Affecting Result Accuracy: Sample hemolysis, delayed processing, or exposure to heat can affect results, leading to false negatives that delay treatment. Medications or concurrent infections may alter antibody levels, requiring clinical correlation and repeat testing if needed.
Clinical Significance: Positive anti-LGI1 confirms autoimmune encephalitis, guiding steroids or plasma exchange to reduce inflammation. A patient with early treatment might avoid permanent memory loss, while untreated cases can lead to death or severe disability. Normal levels may require MRI or additional antibody tests to rule out other causes.
Specialist Consultation: Consult a neurologist or immunologist for result interpretation and management, particularly for middle-aged patients, where tailored therapy and brain monitoring are critical.
Additional Supporting Tests: Brain MRI, EEG, or anti-CASPR2 antibody test to confirm diagnosis and assess brain activity, aiding in comprehensive care and monitoring treatment response.
Test Limitations: Non-specific for encephalitis subtype; clinical correlation with imaging and symptoms is needed. Sensitivity varies with disease stage, and false negatives may occur in early phases, requiring follow-up testing.
References: NINDS Guidelines, 2023; Journal of Neurology, Vincent A, 2022.
